掘金创新药｜君实生物CD112R单抗申报临床：全球仅两个药物获批临床，已有医药巨头伺机布局

七印授权

3UBG3J52OWJP332FBF7BGBPRE5XLL6H3XJ32BLW130BG4DTCDD

2021-12-13 05:23:16

article

23B22B05D9626765C7A53716D5A188261706DD419B955A0ABC9878035496DC95

zh-CN

7ECAEAACF51738AEB7C8867D8E1CEADECD0D2F4E

10882750

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

b0f94f36ffdab98c5565f2b7c7f8c4a355cfdb7125c0878f6052c082bb4c651b2ca9a9921e90ceb66e314fec18975ad81099c588fdddd0f76fd36cc6acf434f21b

{"parameters":{"adaptation":"n","authorized":"七印信息科技","price":"300000"},"type":"cm"}

yuanben_61b6d8c4180a00.70389041

原本认证

54FU36NFMZ6VAJI3G3U5GVDQAA1PEMJ293DFAO1AFA0MWSLLWI

https://www.yuanben.io/article/ce2608b4-7c04-4197-aef6-37e019e98f0d

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}